Osteoporosis, bone & mineral

Impact of standard versus cyclic teriparatide and denosumab treatment on trabecular bone score: a post-hoc analysis of a randomized clinical trial

Osteoporos IntPublished Post-hoc analysis of a randomised controlled trial

Authors' conclusion

TBS improved similarly with cyclic and standard treatment regimens of TPTD and denosumab over 36 months, however possible differences may have been masked by inadequate study power.

Study context

Population
Postmenopausal women with osteoporosis50 completed 36 months
Participants
70 women
Comparison
Cyclic TPTD (three 6-month cycles, each followed by denosumab) vs standard TPTD for 18 months followed by denosumab for 18 months
  • Cyclicn = 32
  • Standardn = 32reference
Primary endpoint
Change in TBS (lumbar spine), cyclic vs standard therapy
Follow-up
36 months

Primary result

As reported in the abstract

TBS increase from baseline · 18 and 36 months
GroupValueP vs baseline, 18 monthsP vs baseline, 36 monthsP vs baseline, 18 and 36 months
Standard1.1% at 18 months; 1.6% at 36 monthsp = 0.11 vs baselinep < 0.11 vs baseline
Cyclic2.4% at 18 months; 2.6% at 36 monthsboth p < 0.05 vs. baseline

Value

Standard1.1% at 18 months; 1.6% at 36 months
Cyclic2.4% at 18 months; 2.6% at 36 months

P vs baseline, 18 months

Standardp = 0.11 vs baseline
Cyclic— not stated in the abstract

P vs baseline, 36 months

Standardp < 0.11 vs baseline
Cyclic— not stated in the abstract

P vs baseline, 18 and 36 months

Standard— not stated in the abstract
Cyclicboth p < 0.05 vs. baseline

Further findings

Baseline Trabecular Bone Score (TBS) (both groups)

Similar between groups; mean level, considered partially degraded
1.24 ± 0.05

Improvement in TBS category · 36 months

Participants with improved TBS category (total)
17
Deteriorations to a lower category
4
No difference between groups in TBS category change

Original publication

Impact of standard versus cyclic teriparatide and denosumab treatment on trabecular bone score: a post-hoc analysis of a randomized clinical trial. Osteoporos Int. Published 20 September 2025. doi:10.1007/s00198-025-07696-7

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.